Document:

EXHIBIT 10.16

 Exhibit 10.16 
 Subscription Agreement 
  

	
	As of July 10, 2007

 To the Board of Directors of 
 Triplecrown Acquisition Corp.: 
 Gentlemen: 
 The undersigned hereby subscribes for and agrees to purchase 2,500,000 Warrants (“Sponsors’ Warrants”) at $1.00 per Sponsors’ Warrant, each to purchase one share of common stock, par value $0.0001
per share, of Triplecrown Acquisition Corp. (the “Corporation”) at $7.50 per share for an aggregate purchase price of $2,500,000 (“Purchase Price”). The purchase and issuance of the Sponsors’ Warrants shall occur
simultaneously with the consummation of the Corporation’s initial public offering of securities (“IPO”) which is being underwritten by Citigroup Global Markets Inc. (“Citigroup”). The Sponsors’ Warrants will be sold to
the undersigned on a private placement basis and not part of the IPO. 
 At least 24 hours prior to the effective date of the registration
statement filed in connection with the IPO (“Registration Statement”), the undersigned shall deliver the Purchase Price to Graubard Miller (“GM”) to hold in a non-interest bearing account until the Corporation consummates the
IPO. Simultaneously with the consummation of the IPO, GM shall deposit the Purchase Price, without interest or deduction, into the trust fund (“Trust Fund”) established by the Corporation for the benefit of the Corporation’s public
stockholders as described in the Corporation’s Registration Statement, pursuant to the terms of an Investment Management Trust Agreement to be entered into between the Corporation and Continental Stock Transfer & Trust Company. In the
event that the IPO is not consummated within 14 days of the date the Purchase Price is delivered to GM, GM shall return the Purchase Price to the undersigned, without interest or deduction. 
 The undersigned represents and warrants that he has been advised that the Sponsors’ Warrants (including the underlying shares of common stock) have
not been registered under the Securities Act; that he is acquiring the Sponsors’ Warrants for his account for investment purposes only; that he has no present intention of selling or otherwise disposing of the Sponsors’ Warrants in
violation of the securities laws of the United States; that he is an “accredited investor” as defined by Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”); and that he is
familiar with the proposed business, management, financial condition and affairs of the Corporation. 
 Moreover, the undersigned agrees that
he shall not sell or transfer the Sponsors’ Warrants or any underlying securities until after the Corporation consummates a merger, capital stock exchange, asset acquisition or other similar business combination with an operating business
(“Business Combination”) meeting the requirements set forth in the Registration Statement and acknowledges that the certificates for such Sponsors’ Warrants shall contain a legend indicating such restriction on transferability.

 The Company hereby acknowledges and agrees that the Sponsors’ Warrants will be exercisable on a cashless basis and, in the event the
Company calls the Warrants for redemption pursuant to that certain Warrant Agreement to be entered into by the Company and Continental Stock Transfer & Trust Company in connection with the Company’s IPO, shall not be redeemable by the
Company so long as such Sponsors’ Warrants are held by the undersigned or his affiliates. 
 The terms of this agreement and the
restriction on transfers with respect to the Sponsors’ Warrants may not be amended without the prior written consent of Citigroup. 

	
	Very truly yours,
	
	  

  

					
	 Agreed to:
  
 Triplecrown Acquisition Corp.

		
	By:	 	 
		 	Name:	 	
		 	Title:	 	
	
	Graubard Miller
		
	By:	 	 
		 	Name:	 	David Alan Miller
		 	Title:	 	Managing Partner
	
	Citigroup Global Markets Inc.
		
	By:	 	 
		 	Name:	 	
		 	Title:Summary of CMGI FY2008 Performance-Based Restricted Stock Bonus Plan

 Exhibit 10.1 
 CMGI, INC. 
 SUMMARY OF FY2008 PERFORMANCE-BASED RESTRICTED STOCK BONUS PLAN 
 On September 18, 2007, the Human Resources and Compensation Committee of the Board of Directors of CMGI, Inc. established a performance-based
restricted stock bonus plan pursuant to which grants of restricted shares of CMGI common stock may be made to certain executive officers of CMGI (as defined by Section 16 of the Securities Exchange Act of 1934, as amended) (other than Joseph C.
Lawler, CMGI’s Chairman, President and Chief Executive Officer). 
 Subject to the achievement of a pre-determined level of Non-GAAP
Operating Income in fiscal year 2008, the executive officers would receive restricted shares of CMGI common stock as follows: 
  

			
	 Name
	  	 Shares

	Steven G. Crane	  	90,000 shares
	Peter L. Gray	  	90,000 shares
	Mark J. Kelly	  	90,000 shares
	William R. McLennan	  	150,000 shares
	David J. Riley	  	90,000 shares
	Scott D. Smith	  	90,000 shares

 The issuance of the restricted shares of CMGI common stock would be made, if at all, on the third
business day following the day CMGI publicly releases its financial results for the fiscal year ending July 31, 2008. Any awards under this bonus plan would vest in three equal installments, on the first, second and third anniversaries of the
grant date.Second License Agreement by and betweent the Registrant and Artes Medical, Inc.

 Exhibit 10.14 
 SECOND 
 LICENSE AGREEMENT 
 This SECOND LICENSE AGREEMENT (“Second Agreement”) is made and entered into as of the 21st day of September, 2007 (“Effective
Date”), by and between BioForm Medical, Inc., a Delaware corporation, and BioForm Medical Europe B.V., a Netherlands corporation (together “BioForm”) and Artes Medical, Inc., a Delaware corporation
(“Artes”). BioForm and Artes shall be collectively referred to herein as the “Parties.” 
 WITNESSETH

 WHEREAS, Artes and BioForm have previously entered into that certain Settlement and License Agreement, dated October 31, 2005 (the
“Agreement”); and 
 WHEREAS, the Parties desire to enter into this separate Second Agreement as set forth herein.

 NOW, THEREFORE, in consideration of the mutual covenants and conditions herein contained and other good and valuable consideration, the
receipt and legal sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 AGREEMENT 
 Unless specifically defined in this Second Agreement, capitalized terms shall have the meanings ascribed to such terms in the Agreement. 
 1. Within ten (10) days following the date of this Second Agreement, BioForm will make an initial payment of Two Million Dollars ($2,000,000)
(“Initial Payment”) to Artes by wire transfer, and BioForm will make a second and final payment of Three Million Five Hundred Thousand Dollars ($3,500,000) (“Final Payment”) to Artes by wire transfer upon the
earlier to occur of (i) thirty (30) days following BioForm’s completion of an initial public offering of its securities pursuant to a registration statement filed with the Securities and Exchange Commission, or (ii) June 30,
2008. 
 2. Artes hereby relinquishes and releases any rights it may have to Royalty payments under Sections 6.1, 6.2, 6.3, 6.4 or 11.4 of
the Agreement that arise from Net Sales occurring after December 31, 2006, including the period between January 1, 2007 and the Effective Date (“Royalty Release”), which Royalty Release shall be effective upon the
Effective Date and at all times thereafter; provided, however, that in the event that either the Initial Payment or Final Payment is not paid when due, the Royalty Release shall be ineffective until such time as such past-due Payment
is made in full whereupon the Royalty Release shall be effective retroactive to the Effective Date. 
 3. Artes hereby confirms that the
license grants to BioForm in Sections 3.1.1.1 and 3.1.1.2 shall be on a paid-up rather than on a royalty-bearing basis at all times that the Royalty Release is effective. Accordingly, Artes waives its rights, and releases BioForm and its 

  

 1 

 
sublicensees from any performance obligations, under Sections 11.2, 11.3.1 through 11.3.4 and 11.4 of the Agreement at all times that the Royalty Release is
effective. For purposes of clarity, Artes retains its rights, and BioForm shall retain its obligations, under Sections 11.3.5 (marking of Sublicensed Products), 11.3.6 (resolution of disputes) and 11.3.7 (validity and enforceability of the Licensed
Patents) of the Agreement. 
 4. Artes hereby relinquishes and releases any rights it may have under the Agreement to records or audits under
Sections 7 and 8 (Records and Audits) of the Agreement with respect to Net Sales occurring after December 31, 2006 at all times that the Royalty Release is effective, but it shall retain its rights under such Sections with respect to Net Sales
that occurred during calendar year 2005 and 2006. 
 5. BioForm hereby releases and relinquishes any rights to royalty reductions under
Section 12.1 of the Agreement with respect to Net Sales occurring after December 31, 2006, but it shall retain its rights under such Section with respect to Net Sales that occurred during calendar years 2005 and 2006. 
 6. In the event that (i) a third party is infringing, or has infringed after the Effective Date, a Licensed Patent in the United States by selling
an implant product containing calcium-hydroxylapatite (CaHA) particles with diameters between 15 and 200 microns, (ii) with respect to such third party’s conduct giving rise to the afore-mentioned infringement, such third party is not also
infringing or has not infringed after the Effective Date any patent owned or licensed (other than a Licensed Patent) by BioForm or any Affiliate of BioForm or any patent under which BioForm has a right of enforcement (“BioForm Patent
Rights”), (iii) BioForm provides notice to Artes in accordance with the notice provisions of the Agreement that BioForm then believes upon reasonable investigation that the third party is not infringing (or has not infringed, as
applicable) any BioForm Patent Rights with respect to the conduct giving rise to the infringement of the Licensed Patent, and (iv) Artes does not commence an infringement action to stop such Infringement within ninety (90) days of receipt
of such notice from BioForm and continue to prosecute diligently such action thereafter, then, in addition to BioForm’s rights under Section 12.3 of the Agreement (Enforcement by BioForm), BioForm shall have the right, at its own expense
and for its own benefit, to enforce and defend the Licensed Patents against the parties responsible for such Infringement and Artes shall provide reasonable cooperation and assistance to BioForm in connection with any such action, including joining
such action if necessary, and BioForm shall retain any damages, including damages for harm to sales of BioForm, its Affiliates, or its sublicensees that are obtained by BioForm in the course of its efforts to stop such Infringement. BioForm’s
right in the preceding sentence to enforce and defend a Licensed Patent against Infringement in the United States shall be limited to infringement actions concerning conduct occurring subsequent to the Effective Date and on or before
September 5, 2011. 
 7. This Second Agreement shall be binding upon and inure to the benefit of the Parties and their respective
successors and assigns. 
 8. Each of Artes and BioForm represent and warrant that (i) the Second Agreement constitutes a legal, valid and
binding obligation on it, enforceable against it in accordance with 

  

 2 

 
this Second Agreement’s terms, (ii) it has obtained any and all consents or approvals that are necessary for it to enter into this Second Agreement
and that it has full and complete authority to enter into this Second Agreement; and (iii) the person signing on its behalf has the full and complete authority to do so. 
 9. Artes represents and warrants that (i) Artes has the sole and exclusive authority to waive and release BioForm and its sublicensee’s
obligations to pay any royalty under the Agreement and (ii) it has not assigned or otherwise transferred to any third party the right to receive any of the royalties under the Agreement. 
 10. The Parties agree that the terms of this Second Agreement are not confidential and may be freely disclosed by the parties to third parties; provided,
however, that public statements (e.g. press releases) shall be limited to the subject matter set forth in Attachment A or such other subject matter as counsel for a party concludes is required to be disclosed pursuant to an applicable law, court
order or government rule or regulation. 
 11. This Second Agreement, together with the Agreement, sets forth the entire understandings of
the parties with respect to the matters set forth herein, and shall supersede any prior negotiations or agreements, whether written or oral, with respect thereto. 
 12. This Second Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to conflicts of law principles. 
 13. The Parties agree that as of the Effective Date any provisions of the Agreement which are not expressly waived or released herein shall remain, with
respect to this Second Agreement, unwaived and not released. Each Party agrees that notwithstanding anything to the contrary in Section 30.3 of the Agreement, this Second Agreement shall be enforceable against such Party. 
 14. This Second Agreement may be executed in more than one counterpart, each of which shall be deemed to be an original but all of which taken together
shall be deemed a single instrument. A facsimile transmission of the signed Second Agreement will be legal and binding on the Parties. 
 IN WITNESS WHEREOF,
this Agreement has been executed and delivered by duly authorized representatives of all parties hereto as of the Effective Date. 
  

							
	“BioForm”:	 	“Artes”:
		
	BioForm Medical, Inc.	 	Artes Medical, Inc.
				
	By:	  	 /s/ Steven L. Basta
	 	By:	 	 /s/ Christopher Reinhard

	Name:	  	Steven L. Basta	 	Name:	 	Christopher Reinhard
	Title:	  	Chief Executive Officer	 	Title:	 	Executive Chairman

  

 3 

 Attachment A 
 [Public Statement] 
 Artes Medical, Inc. and BioForm Medical, Inc. today announced that BioForm has elected
to pre-pay all future royalty obligations to Artes by making two payments totaling $5.5 million. These payments will replace any future royalty obligation of BioForm to Artes under the October 31, 2005 settlement and license agreement between
the companies. 
  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]